Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ORIC Oric Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ORIC
Price (delayed)
$10.8
Market cap
$767.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.87
Enterprise value
$718.42M
ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist
Highlights
The quick ratio has declined by 45% year-on-year but it has grown by 12% since the previous quarter
Oric Pharmaceuticals's equity has decreased by 33% YoY and by 10% QoQ
ORIC's net income is down by 31% year-on-year and by 3.9% since the previous quarter
Key stats
What are the main financial stats of ORIC
Market
Valuations
Earnings
Shares outstanding
71.09M
Market cap
$767.75M
Enterprise value
$718.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$146.62M
Net income
-$132.86M
EBIT
-$132.86M
EBITDA
-$131.71M
Free cash flow
-$116.37M
Per share
Balance sheet
Liquidity
EPS
-$1.87
EPS diluted
-$1.87
Free cash flow per share
-$1.64
Book value per share
$3.09
Revenue per share
$0
TBVPS
$3.42
Total assets
$242.86M
Total liabilities
$23.12M
Debt
$0
Equity
$219.74M
Working capital
$193.82M
Debt to equity
0
Current ratio
12
Quick ratio
11.56
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.3%
Return on equity
-51.1%
Return on invested capital
-61.7%
Return on capital employed
-59%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORIC stock price
How has the Oric Pharmaceuticals stock price performed over time
Intraday
1.41%
1 week
2.86%
1 month
28.57%
1 year
43.62%
YTD
33.83%
QTD
6.4%
Financial performance
How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$146.62M
Net income
-$132.86M
Gross margin
N/A
Net margin
N/A
ORIC's net income is down by 31% year-on-year and by 3.9% since the previous quarter
The operating income has declined by 29% year-on-year and by 2.6% since the previous quarter
Price vs fundamentals
How does ORIC's price correlate with its fundamentals
Growth
What is Oric Pharmaceuticals's growth rate over time
Valuation
What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 3.3% year-on-year and by 2.2% since the previous quarter
The stock's P/B is 66% more than its 5-year quarterly average of 2.1 and 66% more than its last 4 quarters average of 2.1
Oric Pharmaceuticals's equity has decreased by 33% YoY and by 10% QoQ
Efficiency
How efficient is Oric Pharmaceuticals business performance
Oric Pharmaceuticals's return on invested capital has decreased by 35% YoY and by 16% QoQ
The return on equity has declined by 34% year-on-year and by 15% since the previous quarter
The ROA has declined by 33% year-on-year and by 14% since the previous quarter
Dividends
What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORIC.
Financial health
How did Oric Pharmaceuticals financials performed over time
The quick ratio has declined by 45% year-on-year but it has grown by 12% since the previous quarter
The company's current ratio fell by 44% YoY but it rose by 14% QoQ
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has decreased by 33% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.